<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Sab Biotherapeutics Inc — News on 6ix</title>
<link>https://6ix.com/company/sab-biotherapeutics-inc</link>
<description>Latest news and press releases for Sab Biotherapeutics Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Wed, 22 Apr 2026 11:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/sab-biotherapeutics-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835bc7a78dffbe2df116cad.webp</url>
<title>Sab Biotherapeutics Inc</title>
<link>https://6ix.com/company/sab-biotherapeutics-inc</link>
</image>
<item>
<title>SAB BIO Presents Additional Clinical and Mechanistic Data from SAB-142 Phase 1 Trial in Adult Patients with Established Autoimmune Type 1 Diabetes at IDS 2026</title>
<link>https://6ix.com/company/sab-biotherapeutics-inc/news/sab-bio-presents-additional-clinical-and-mechanistic-data-from-sab-142-phase-1-trial-in-adult-patients-with-established-autoimmune-type-1-diabetes-at-ids-2026</link>
<guid isPermaLink="true">https://6ix.com/company/sab-biotherapeutics-inc/news/sab-bio-presents-additional-clinical-and-mechanistic-data-from-sab-142-phase-1-trial-in-adult-patients-with-established-autoimmune-type-1-diabetes-at-ids-2026</guid>
<pubDate>Wed, 22 Apr 2026 11:00:00 GMT</pubDate>
<description>All 4 T1D participants receiving SAB-142 showed C-peptide preservation with 3 of the 4 participants showing a super responder profile concomitant with T cell exhaustion T1D participants receiving SAB-142 showed improved glycemic control MIAMI, April 22, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today presented a</description>
</item>
<item>
<title>SAB BIO to Present Additional Data Supporting the Unique Profile of SAB-142 at the 2026 Immunology of Diabetes Society Congress</title>
<link>https://6ix.com/company/sab-biotherapeutics-inc/news/sab-bio-to-present-additional-data-supporting-the-unique-profile-of-sab-142-at-the-2026-immunology-of-diabetes-society-congress</link>
<guid isPermaLink="true">https://6ix.com/company/sab-biotherapeutics-inc/news/sab-bio-to-present-additional-data-supporting-the-unique-profile-of-sab-142-at-the-2026-immunology-of-diabetes-society-congress</guid>
<pubDate>Wed, 15 Apr 2026 04:00:00 GMT</pubDate>
<description>MIAMI, April 15, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a fully human</description>
</item>
<item>
<title>SAB BIO Announces Closing of $85 Million Public Offering of Common Stock and Pre-Funded Warrants</title>
<link>https://6ix.com/company/sab-biotherapeutics-inc/news/sab-bio-announces-closing-of-dollar85-million-public-offering-of-common-stock-and-pre-funded-warrants</link>
<guid isPermaLink="true">https://6ix.com/company/sab-biotherapeutics-inc/news/sab-bio-announces-closing-of-dollar85-million-public-offering-of-common-stock-and-pre-funded-warrants</guid>
<pubDate>Thu, 19 Mar 2026 04:00:00 GMT</pubDate>
<description>MIAMI, March 19, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a fully human</description>
</item>
<item>
<title>SAB BIO Announces Pricing of $85 Million Public Offering of Common Stock and Pre-Funded Warrants</title>
<link>https://6ix.com/company/sab-biotherapeutics-inc/news/sab-bio-announces-pricing-of-dollar85-million-public-offering-of-common-stock-and-pre-funded-warrants</link>
<guid isPermaLink="true">https://6ix.com/company/sab-biotherapeutics-inc/news/sab-bio-announces-pricing-of-dollar85-million-public-offering-of-common-stock-and-pre-funded-warrants</guid>
<pubDate>Tue, 17 Mar 2026 04:00:00 GMT</pubDate>
<description>MIAMI, March 17, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a fully human</description>
</item>
<item>
<title>SAB BIO Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants</title>
<link>https://6ix.com/company/sab-biotherapeutics-inc/news/sab-bio-announces-proposed-public-offering-of-common-stock-and-pre-funded-warrants</link>
<guid isPermaLink="true">https://6ix.com/company/sab-biotherapeutics-inc/news/sab-bio-announces-proposed-public-offering-of-common-stock-and-pre-funded-warrants</guid>
<pubDate>Tue, 17 Mar 2026 04:00:00 GMT</pubDate>
<description>MIAMI, March 17, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a fully human</description>
</item>
<item>
<title>SAB BIO Announces Additional Phase 1 Data for SAB-142 in Adult Patients with Established Autoimmune Type 1 Diabetes</title>
<link>https://6ix.com/company/sab-biotherapeutics-inc/news/sab-bio-announces-additional-phase-1-data-for-sab-142-in-adult-patients-with-established-autoimmune-type-1-diabetes-3</link>
<guid isPermaLink="true">https://6ix.com/company/sab-biotherapeutics-inc/news/sab-bio-announces-additional-phase-1-data-for-sab-142-in-adult-patients-with-established-autoimmune-type-1-diabetes-3</guid>
<pubDate>Tue, 10 Mar 2026 04:00:00 GMT</pubDate>
<description>Results demonstrated early signals of C-peptide preservation T1D key opinion leader, Michael J. Haller, MD, provided a recorded webinar reviewing the SAB-142</description>
</item>
<item>
<title>SAB BIO Reports Full Year 2025 Financial Results and Business Highlights</title>
<link>https://6ix.com/company/sab-biotherapeutics-inc/news/sab-bio-reports-full-year-2025-financial-results-and-business-highlights</link>
<guid isPermaLink="true">https://6ix.com/company/sab-biotherapeutics-inc/news/sab-bio-reports-full-year-2025-financial-results-and-business-highlights</guid>
<pubDate>Mon, 09 Mar 2026 04:00:00 GMT</pubDate>
<description>Advanced SAB -142 into registrational Phase 2b SAFEGUARD study with multiple patients dosed; enrollment ongoing and on track to complete enrollment by end of</description>
</item>
<item>
<title>SAB BIO to Participate in Upcoming Investor Conferences</title>
<link>https://6ix.com/company/sab-biotherapeutics-inc/news/sab-bio-participate-upcoming-investor-140000036</link>
<guid isPermaLink="true">https://6ix.com/company/sab-biotherapeutics-inc/news/sab-bio-participate-upcoming-investor-140000036</guid>
<pubDate>Wed, 04 Feb 2026 14:00:00 GMT</pubDate>
<description>MIAMI, Feb. 04, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today announced that members of its management team will participate in the following investor conferences in February: Guggenheim Securities Emerging Outlook: Biotech SummitDate: February 11, 2026Time: 10:30 a.m. ETFormat: Fireside ChatLocation: New York</description>
</item>
<item>
<title>SAB BIO Strengthens Board of Directors with Appointment of New Chair and New Director</title>
<link>https://6ix.com/company/sab-biotherapeutics-inc/news/sab-bio-strengthens-board-directors-130000353</link>
<guid isPermaLink="true">https://6ix.com/company/sab-biotherapeutics-inc/news/sab-bio-strengthens-board-directors-130000353</guid>
<pubDate>Wed, 07 Jan 2026 13:00:00 GMT</pubDate>
<description>David Zaccardelli, Pharm.D. joins Board as Chair Rita Jain, M.D., joins Board as an Independent Director MIAMI, Jan. 07, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today announced the appointment of David Zaccardelli, Pharm.D. to its Board of Directors as Chair of the Board and the appointment of Rita Jain, M.D.,</description>
</item>
<item>
<title>SAB BIO to Present at the 44th Annual J.P. Morgan Healthcare Conference</title>
<link>https://6ix.com/company/sab-biotherapeutics-inc/news/sab-bio-present-44th-annual-130000613</link>
<guid isPermaLink="true">https://6ix.com/company/sab-biotherapeutics-inc/news/sab-bio-present-44th-annual-130000613</guid>
<pubDate>Tue, 06 Jan 2026 13:00:00 GMT</pubDate>
<description>MIAMI, Jan. 06, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today announced that the Company’s CEO Samuel J. Reich will present at the 44th Annual J.P. Morgan Healthcare Conference on Thursday, January 15 at 7:30 a.m. PT/10:30 a.m. ET in San Francisco, CA. A live webcast of the presentation will be available in the “Inves</description>
</item>
<item>
<title>First Patient Dosed in SAB BIO’s SAFEGUARD Clinical Trial of SAB-142 for the Treatment of Stage 3 T1D</title>
<link>https://6ix.com/company/sab-biotherapeutics-inc/news/first-patient-dosed-sab-bio-130000523</link>
<guid isPermaLink="true">https://6ix.com/company/sab-biotherapeutics-inc/news/first-patient-dosed-sab-bio-130000523</guid>
<pubDate>Thu, 18 Dec 2025 13:00:00 GMT</pubDate>
<description>Enrollment in the SAFEGUARD trial is ongoing at multiple centers globallyCompany on-track to share Phase 2b data in 2H 2027 MIAMI, Dec. 18, 2025 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today announced the dosing of the first patient with SAB-142 in the Phase 2b registrational SAFety and Efficacy of human anti-thymocyte imm</description>
</item>
<item>
<title>SAB BIO Announces Positive Confirmatory Clinical Results from the Phase 1 Study of SAB-142 in Development for the Treatment of Stage 3 T1D</title>
<link>https://6ix.com/company/sab-biotherapeutics-inc/news/sab-bio-announces-positive-confirmatory-130000867</link>
<guid isPermaLink="true">https://6ix.com/company/sab-biotherapeutics-inc/news/sab-bio-announces-positive-confirmatory-130000867</guid>
<pubDate>Wed, 17 Dec 2025 13:00:00 GMT</pubDate>
<description>Phase 1 data confirms SAB-142 does not cause serum sickness and has low/no immunogenicity at any dose and in all cohorts, including redosed healthy volunteersStudy results support the chronic dosing of SAB-142 in an outpatient setting for the treatment of stage 3 autoimmune type 1 diabetesPhase 2b SAFEGUARD trial underway and recruiting at multiple sites around the world MIAMI, Dec. 17, 2025 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company</description>
</item>
<item>
<title>SAB BIO to Present Data Showcasing Progress in the Development of SAB-142 at the Asian Conference on Innovative Therapies for Diabetes Management</title>
<link>https://6ix.com/company/sab-biotherapeutics-inc/news/sab-bio-present-data-showcasing-130000691</link>
<guid isPermaLink="true">https://6ix.com/company/sab-biotherapeutics-inc/news/sab-bio-present-data-showcasing-130000691</guid>
<pubDate>Mon, 08 Dec 2025 13:00:00 GMT</pubDate>
<description>MIAMI, Dec. 08, 2025 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today announced that the Company will give several oral presentations at the 2nd Asian Conference on Innovative Therapies for Diabetes Management (ATTD-Asia) being held December 9-11, 2025, in Singapore. Data to be presented will highlight the progress of SAB BIO</description>
</item>
<item>
<title>SAB BIO Reports Third Quarter Financial Results and Recent Business Highlights</title>
<link>https://6ix.com/company/sab-biotherapeutics-inc/news/sab-bio-reports-third-quarter-220000826</link>
<guid isPermaLink="true">https://6ix.com/company/sab-biotherapeutics-inc/news/sab-bio-reports-third-quarter-220000826</guid>
<pubDate>Thu, 13 Nov 2025 22:00:00 GMT</pubDate>
<description>Initiated registrational Phase 2b SAFEGUARD trial of SAB-142 in new-onset, Stage 3 autoimmune T1D patientsMultiple SAFEGUARD trial sites activated; on-track to dose first patient by year-endRecent data presented at EASD and IPSAD provide further validation for SAB-142 as a novel, potentially best-in-class, disease-modifying, immunotherapeutic approach to redefine treatment of Stage 3 T1DStrong cash position with operational runway through 2028, enabling completion of registrational Phase 2b SAFE</description>
</item>
<item>
<title>SAB BIO to Present Data at the International Society for Pediatric and Adolescent Diabetes Annual Conference Showcasing Progress in the Development of SAB-142</title>
<link>https://6ix.com/company/sab-biotherapeutics-inc/news/sab-bio-present-data-international-133000116</link>
<guid isPermaLink="true">https://6ix.com/company/sab-biotherapeutics-inc/news/sab-bio-present-data-international-133000116</guid>
<pubDate>Tue, 04 Nov 2025 13:30:00 GMT</pubDate>
<description>MIAMI, Nov. 04, 2025 (GLOBE NEWSWIRE) -- SAb Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today announced that four oral presentations and two poster presentations have been accepted for presentation at the 51st Annual Conference of the International Society for Pediatric and Adolescent Diabetes (ISPAD) being held November 5-8, 2025 in Montréal, Canad</description>
</item>
<item>
<title>SAB BIO Highlights Data in Multiple Presentations at EASD</title>
<link>https://6ix.com/company/sab-biotherapeutics-inc/news/sab-bio-highlights-data-multiple-112400638</link>
<guid isPermaLink="true">https://6ix.com/company/sab-biotherapeutics-inc/news/sab-bio-highlights-data-multiple-112400638</guid>
<pubDate>Fri, 19 Sep 2025 11:24:00 GMT</pubDate>
<description>-As SAB initiates its Phase 2b SAFEGUARD study for SAB-142 in new-onset Stage 3 autoimmune T1D patients, EASD provided an opportunity to connect with many T1D thought leaders that will participate in the study- -Data in multiple SAB presentations and INNODIA’s MELD-ATG study provide further validation for SAB-142 as a novel, potentially best-in-class, disease-modifying immunotherapeutic approach poised to redefine treatment of T1D- MIAMI, Sept. 19, 2025 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, I</description>
</item>
<item>
<title>SAB BIO to Deliver Five Presentations Related to SAB-142 at the 2025 Annual Meeting of the European Association for the Study of Diabetes</title>
<link>https://6ix.com/company/sab-biotherapeutics-inc/news/sab-bio-deliver-five-presentations-200500200</link>
<guid isPermaLink="true">https://6ix.com/company/sab-biotherapeutics-inc/news/sab-bio-deliver-five-presentations-200500200</guid>
<pubDate>Wed, 03 Sep 2025 20:05:00 GMT</pubDate>
<description>MIAMI, Sept. 03, 2025 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), (“SAB BIO” or the “Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing a multi-specific human anti-thymocyte immunoglobulin (hIgG) for delaying the onset and progression of autoimmune type 1 diabetes (T1D), today announced that it will present at the 61st Annual Meeting of the European Association for the Study of Diabetes (EASD) being held September 15 – 1</description>
</item>
<item>
<title>SAB BIO Reports Second Quarter Financial Results and Highlights Company Updates</title>
<link>https://6ix.com/company/sab-biotherapeutics-inc/news/sab-bio-reports-second-quarter-113000647</link>
<guid isPermaLink="true">https://6ix.com/company/sab-biotherapeutics-inc/news/sab-bio-reports-second-quarter-113000647</guid>
<pubDate>Thu, 07 Aug 2025 11:30:00 GMT</pubDate>
<description>Recently raised $175 million in oversubscribed private placement which included strategic investor Sanofi and top-tier biotech investors Strong cash position with completed financing extending operational runway until the middle of 2028 Achieved alignment with FDA on the design and advancement of Phase 2b SAFety and Efficacy of human anti-thymocyte immunoGlobUlin SAB-142 ARresting progression of type 1 Diabetes (SAFEGUARD) study following a constructive Type B meeting SAFEGUARD study to initiate</description>
</item>
<item>
<title>SAB BIO Announces Oversubscribed $175 Million Private Placement</title>
<link>https://6ix.com/company/sab-biotherapeutics-inc/news/sab-bio-announces-oversubscribed-175-113000201</link>
<guid isPermaLink="true">https://6ix.com/company/sab-biotherapeutics-inc/news/sab-bio-announces-oversubscribed-175-113000201</guid>
<pubDate>Mon, 21 Jul 2025 11:30:00 GMT</pubDate>
<description>Participation from strategic investor Sanofi, along with new investors RA Capital Management, Commodore Capital, Vivo Capital, Blackstone Multi-Asset Investing, Spruce Street Capital, Forge Life Science Partners and Woodline Partners LP, and existing investors Sessa Capital, the T1D Fund, and ATW Partners Proceeds expected to fully fund completion of pivotal Phase 2b SAFEGUARD study evaluating SAB-142 for delaying progression of autoimmune T1D in newly diagnosed T1D patients (Stage 3) Company ex</description>
</item>
<item>
<title>SAB BIO Announces Q1 2025 Financial Results and Provides Company Updates</title>
<link>https://6ix.com/company/sab-biotherapeutics-inc/news/sab-bio-announces-q1-2025-130000052</link>
<guid isPermaLink="true">https://6ix.com/company/sab-biotherapeutics-inc/news/sab-bio-announces-q1-2025-130000052</guid>
<pubDate>Fri, 09 May 2025 13:00:00 GMT</pubDate>
<description>MIAMI, May 09, 2025 (GLOBE NEWSWIRE) -- SAB BIO (Nasdaq: SABS), (“SAB BIO” or the “Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of type 1 diabetes (T1D), today announced financial results for the quarter ending March 31, 2025, and reported on recent developments. Samuel J. Reich, Chairman and CEO of SAB BIO, stated, “We have made strong progress this qu</description>
</item>
</channel>
</rss>